{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:28:01Z","timestamp":1793600881599,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017723","name":"Innovent Biologics Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jaad.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:38:42Z","timestamp":1775230722000},"page":"87-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis"],"prefix":"10.1016","volume":"95","author":[{"given":"Yunlu","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanying","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rixin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Han-Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2026.04.001_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.jaad.2026.04.001_bib2","first-page":"449","article-title":"Prevalence and risk factors of atopic dermatitis, psoriasis, acne, and urticaria in China","volume":"45","author":"Chen","year":"2020","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.jaad.2026.04.001_bib3","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"issue":"28","key":"10.1016\/j.jaad.2026.04.001_bib4","doi-asserted-by":"crossref","first-page":"46381","DOI":"10.18632\/oncotarget.18453","article-title":"Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.jaad.2026.04.001_bib5","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"8","author":"Sbidian","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.jaad.2026.04.001_bib6","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1097\/CM9.0000000000002873","article-title":"Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: a 12-week randomized placebo-controlled phase III trial with long-term extension","volume":"137","author":"Yu","year":"2024","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"10.1016\/j.jaad.2026.04.001_bib7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10148","key":"10.1016\/j.jaad.2026.04.001_bib8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"Pt B","key":"10.1016\/j.jaad.2026.04.001_bib9","article-title":"IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis","volume":"89","author":"Li","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10.1016\/j.jaad.2026.04.001_bib10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/13543784.2023.2230122","article-title":"Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study","volume":"32","author":"He","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"issue":"1-2","key":"10.1016\/j.jaad.2026.04.001_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1081\/BIP-100104194","article-title":"Accounting for dropout bias using mixed-effects models","volume":"11","author":"Mallinckrodt","year":"2001","journal-title":"J Biopharm Stat"},{"issue":"1","key":"10.1016\/j.jaad.2026.04.001_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2247106","article-title":"The economic burden and quality of life of patients with psoriasis treated with biologics in China","volume":"34","author":"Min","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2026.04.001_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12954-019-0312-8","article-title":"Reducing injection intensity is associated with decreased risk for invasive bacterial infection among high-frequency injection drug users","volume":"16","author":"Islam","year":"2019","journal-title":"Harm Reduct J"},{"issue":"4","key":"10.1016\/j.jaad.2026.04.001_bib14","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226005153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226005153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:44:07Z","timestamp":1793598247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226005153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0190962226005153"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.04.001","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}